Westpac Banking Corp Invests $4.40 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Westpac Banking Corp acquired 7,059 Regeneron shares worth approximately $4.4 million during the second quarter. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 and revenue of $4.29 billion, both exceeding estimates; revenue increased 16.7% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $801.70.
• The company received FDA approval for Pasatru, expanding its rare-disease portfolio, and is pursuing obesity-treatment opportunities. However, litigation concerning alleged disclosures about the Fianlimab-Libtayo trial presents ongoing legal and reputational risks.

Westpac Banking Corp acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,059 shares of the biopharmaceutical company's stock, valued at approximately $4,402,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. TRB Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $206,000. Sumitomo Life Insurance Co. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $503,000. Landscape Capital Management L.L.C. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $289,000. Korea Investment CORP purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $46,737,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $811,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is currently owned by insiders.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research report on Monday, May 18th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $801.70.

Regeneron Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ REGN opened at $834.04 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $847.00. The firm's 50 day moving average price is $697.09 and its 200 day moving average price is $716.73. The firm has a market cap of $85.87 billion, a P/E ratio of 20.61, a price-to-earnings-growth ratio of 1.41 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. During the same period in the previous year, the company earned $12.81 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 16.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source